Public Citizen says US government must investigate clinical trials of a Novartis drug

20 July 2011

The Food and Drug Administration and the Office for Human Research Protections (OHRP), which is housed in the Department of Health and Human Services, “should suspend studies of a dangerous drug and promptly investigate allegations that these studies are unethical and fail to comply with federal regulations that protect human subjects,” health advocacy Public Citizen said today in letters to the two agencies.

One of the studies involves children, which raises serious ethical concerns and appears to violate special federal regulations designed to protect children in research, said Michael Carome, deputy director of Public Citizen’s Health Research Group. The drug, Ilaris (canakinumab), is manufactured by Swiss drug major Novartis (NOVN: VX) and approved by the FDA only for treating a group of rare serious genetic disorders called cryopyrin-associated periodic syndromes, which cause widespread inflammation in the body.

Ilaris approved in EU, but got negative review from FDA advisory panel

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical